Polaris expands ADI-PEG anticancer collaboration with Ludwig Institute
This article was originally published in Scrip
Executive Summary
Privately held Polaris Group is expanding its longstanding collaboration with the Ludwig Institute for Cancer Research (LICR) to further explore the potential of its investigational anticancer, pegylated arginine deiminase (ADI-PEG 20).